While the glaucoma market is dominated by drops and lasers, Iantrek is surgically carving out a distinct, high-margin niche. Their website is sparse, but the data tells a story of a company deeply focused on the uveoscleral pathway—a surgical approach that bypasses the eye's conventional drainage systems.

"In a market obsessed with 'drop-free' solutions, Iantrek is betting that the real money is in the operating room, not the pharmacy."

The leadership team, led by CEO Adam Szaronos, appears to be building a classic medtech vertical. The presence of a Regional Sales Director (East) and an Associate Marketing Director confirms a direct-to-clinic sales motion. They aren't marketing to the masses; they are selling to surgeons.

• Revenue per Employee: ~$76k (indicative of a pre-scale R&D or early commercial phase).
• Tech Stack: Relies heavily on AWS CloudFront and Cloudflare, suggesting a lightweight, scalable digital infrastructure.
• Search Intent: High specificity in keywords indicates a narrow, well-defined target audience.